JPS637552B2 - - Google Patents
Info
- Publication number
- JPS637552B2 JPS637552B2 JP58176361A JP17636183A JPS637552B2 JP S637552 B2 JPS637552 B2 JP S637552B2 JP 58176361 A JP58176361 A JP 58176361A JP 17636183 A JP17636183 A JP 17636183A JP S637552 B2 JPS637552 B2 JP S637552B2
- Authority
- JP
- Japan
- Prior art keywords
- water
- mixture
- propyltriethoxysilane
- chloroethyl
- sulfamoylphenylureido
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Description
本発明は新規な化合物である置換フエニルウレ
イドプロピルトリアルコキシシラン、すなわち、
一般式
〔ただし、Rはアルキル基、Xはスルフアモイ
ル基またはビス(β−クロロエチル)アミノ基で
ある〕で示される置換フエニルウレイドプロピル
トリアルコキシシランを提供するものである。
従来、官能性アルキルシラン化合物、例えばγ
−アミノプロピルトリエトキシシラン、γ−(グ
リシジルオキシ)プロピルトリエトキシシランな
どの官能性プロピルシラン化合物は繊維表面など
への撥水処理剤、防錆剤等に使用されることが知
られている。さらに、γ−アミノプロピルトリエ
トキシシランと有機イソシアネートとを反応させ
ることによつて得られる、一般式
(ただし、Arは有機基を表わす)で示される
γ−(有機ウレイド)プロピルトリエトキシシラ
ンもまた米国特許第2907782号に示されるように
公知な化合物である。しかし、これらの公知文献
においては、有機珪素化合物の生理活性まで述べ
たものはない。
本発明者は長年有用な種々の官能性有機珪素化
合物の合成研究を続けて来た。その結果一般式、
(RO)3SiCH2CH2CH2NCO(ただし、Rはアルキ
ル基である)で示されるγ−イソシアナートプロ
ピルトリアルコキシシランと、一般式、
The present invention is a novel compound substituted phenylureidopropyltrialkoxysilane, namely:
general formula [However, R is an alkyl group, and X is a sulfamoyl group or a bis(β-chloroethyl)amino group]. Traditionally, functional alkylsilane compounds, such as γ
It is known that functional propylsilane compounds such as -aminopropyltriethoxysilane and γ-(glycidyloxy)propyltriethoxysilane are used as water repellent treatment agents for fiber surfaces, rust preventive agents, and the like. Furthermore, the general formula obtained by reacting γ-aminopropyltriethoxysilane and an organic isocyanate γ-(organoureido)propyltriethoxysilane (where Ar represents an organic group) is also a known compound as shown in US Pat. No. 2,907,782. However, none of these known documents describes the physiological activity of organosilicon compounds. The present inventors have continued research on the synthesis of various useful functional organosilicon compounds for many years. As a result, the general formula,
(RO) 3 SiCH 2 CH 2 CH 2 NCO (however, R is an alkyl group) γ-isocyanatopropyltrialkoxysilane and the general formula,
(CH3CH2)3N
〔8.6〕
以上の結果から、得られた白色固体がγ−〔p
−(ビス−β−クロロエチル)アミノフエニルウ
レイド〕プロピルトリエトキシシランとトリエチ
ルアミン・塩酸塩との1:1モル比混合物である
ことが明らかとなつた。
該白色固体(7.12g)を乳鉢に移し、水(50
ml)を加えてよく砕きかき混ぜた後吸引濾過し
た。濾取固体について同様な操作をさらに3回繰
り返し行つた。濾液から水を減圧留去することに
より、白色の針状晶を得た。元素分析を行つたと
ころ、C51.35%,H11.71%,N10.08%なる測定
値が得られC6H16NCl(137.66)なる組成式に対す
る計算値C52.35%,H11.72%,N10.18%によく
一致した。さらに赤外吸収スペクトルを測定し、
標品と比較することにより、濾液から得られた該
結晶がトリエチルアミンの塩酸塩であることが明
らかとなつた。
また、濾取固体につき、 13C−核磁気共鳴スペ
クトルを重クロロホルム中において測定したとこ
ろ、46.0ppm及び8.6ppmのピークが消失した以
外は前に記載した測定結果によく一致した。ま
た、赤外吸収スペクトルにおいてトリエチルアミ
ンの塩酸塩による2800〜2300cm-1領域の特徴的な
数本のピークが消失した。
以上の結果から、水洗によつて得られた固体が
トリエチルアミンの塩酸塩を含まないγ−〔p−
(ビス−β−クロロエチル)アミノフエニルウレ
イド〕プロピルトリエトキシシランであることが
明らかとなつた。
実施例 3
γ−アミノプロピルトリエトキシシラン(3.45
g,0.016mole)のエーテル溶液(30ml)にp−
スルフアモイルフエニルイソシアネート(3.09
g,0.016mole)のエーテル溶液を氷水冷下に滴
下した後、室温で一夜撹拌した。さらに該反応混
合物を5時間加熱還流した。溶媒を蒸留すること
により除き、白色固体(6.54g)を得た。該固体
につき、赤外吸収スペクトル及び質量スペクトル
を測定することにより、該固体が実施例1で得ら
れた生成物と同一、すなわち、γ−(P−スルフ
アモイルフエニルウレイド)プロピルトリエトキ
シシランであることが明らかとなつた。
実施例 4
実施例1〜3で記載したのと同様な方法によ
り、種々の置換フエニルウレイドプロピルトリア
ルコキシシランを合成した。得られた置換フエニ
ルウレイドプロピルトリアルコキシシランを、元
素分析結果、反応原料組成及び反応条件と共に第
1表に略記した。なお、フエニル側の置換基
(X)が同一である場合には、該プロピルトリア
ルコキシシランの赤外吸収スペクトルはアルコキ
シ基と構成するアルキル結合に基づく吸収領域
(3000〜2800cm-1)に若干の差異が認められる以
外はほとんど同一であつた。さらに該プロピルト
リアルコキシシランの質量スペクトルにおいて
は、弱い分子イオンピーク(M)とトリアルコ
キシシリル結合に基づく、比較的強いピーク
〔(RO)3Si〕が認められた。ただし、該分子イ
オンピークは分子量が大きくなる程弱くなる傾向
にあり、該分子量が500以上である場合にはほと
んど観察されなかつた。
(CH 3 CH 2 ) 3 N [8.6] From the above results, the white solid obtained is γ-[p
-(Bis-β-chloroethyl)aminophenylureido] It was found to be a 1:1 molar mixture of propyltriethoxysilane and triethylamine hydrochloride. Transfer the white solid (7.12 g) to a mortar and add water (50 g) to a mortar.
ml) was added, crushed well and stirred, followed by suction filtration. The same operation was repeated three more times for the solids collected by filtration. White needle-like crystals were obtained by distilling off water from the filtrate under reduced pressure. When elemental analysis was performed, the measured values were C51.35%, H11.71%, N10.08%, and the calculated values were C52.35%, H11.72% for the composition formula C 6 H 16 NCl (137.66). , N10.18%. Furthermore, we measured the infrared absorption spectrum,
Comparison with the standard product revealed that the crystals obtained from the filtrate were triethylamine hydrochloride. Furthermore, when the 13 C-nuclear magnetic resonance spectrum of the filtered solid was measured in deuterated chloroform, the results were in good agreement with the measurement results described above, except that the peaks at 46.0 ppm and 8.6 ppm disappeared. Furthermore, several characteristic peaks in the 2800 to 2300 cm -1 region due to triethylamine hydrochloride disappeared in the infrared absorption spectrum. From the above results, it is clear that the solid obtained by washing with water does not contain triethylamine hydrochloride.
It was revealed that it was (bis-β-chloroethyl)aminophenylureido]propyltriethoxysilane. Example 3 γ-Aminopropyltriethoxysilane (3.45
g, 0.016 mole) in ether solution (30 ml) of p-
Sulfamoyl phenyl isocyanate (3.09
An ether solution of 0.016 g, 0.016 mole) was added dropwise to the mixture under ice-water cooling, and the mixture was stirred overnight at room temperature. The reaction mixture was further heated under reflux for 5 hours. The solvent was removed by distillation to give a white solid (6.54g). By measuring the infrared absorption spectrum and mass spectrum of the solid, it was determined that the solid was the same as the product obtained in Example 1, that is, γ-(P-sulfamoylphenylureido)propyltriethoxysilane. It became clear that. Example 4 Various substituted phenylureidopropyltrialkoxysilanes were synthesized by methods similar to those described in Examples 1-3. The obtained substituted phenylureidopropyltrialkoxysilane is summarized in Table 1 along with the elemental analysis results, reaction raw material composition, and reaction conditions. In addition, when the substituents (X) on the phenyl side are the same, the infrared absorption spectrum of the propyltrialkoxysilane has a slight difference in the absorption region (3000 to 2800 cm -1 ) based on the alkoxy group and the constituent alkyl bond. They were almost the same except for some differences. Furthermore, in the mass spectrum of the propyltrialkoxysilane, a weak molecular ion peak (M) and a relatively strong peak [(RO) 3 Si] based on the trialkoxysilyl bond were observed. However, the molecular ion peak tends to become weaker as the molecular weight increases, and was hardly observed when the molecular weight was 500 or more.
【表】【table】
【表】
参考例 1
実施例1で得たγ−(p−スルフアモイルフエ
ニルウレイド)プロピルトリエトキシシラン
(9.07g,0.022mole)にメタノール(50ml)及び
水(30ml)を加え、室温にて一夜撹拌した後、水
浴上で1時間60℃に加熱した。反応混合物から低
沸点物を減圧留去し、次いで70℃で5時間真空乾
燥することにより、γ−(p−スルフアモイルフ
エニルウレイド)プロピルポリシルセスキオキサ
ン(6.32g)を白色固体として得た。
参考例 2
実施例で得られたγ−〔p−(ビス−β−クロロ
エチル)アミノフエニルウレイド〕プロピルトリ
エトキシシランとトリメチルアミン塩酸塩との
1:1混合物(4.00g)をメタノール(200ml)
に溶かし、水(50ml)を加えて2日間室温にて撹
拌した。メタノールを減圧留去し、残渣から水を
傾斜により除去した。水(約100ml)を加え、フ
ラスコに付着したガム状物を洗つた。該洗浄操作
を4回繰り返した後、ガム状態を真空乾燥するこ
とによりγ−〔p−(ビス−β−クロロエチル)ア
ミノフエニルウレイド〕プロピルポリシスセスキ
オキサン(2.11g)をピンク色固体として得た。
応用例 1
参考例1で得られたγ−(p−スルフアモイル
フエニルウレイド)プロピルポリシルセスキオキ
サンを界面活性剤ツイーン80を含む生理食塩水
(0.85%)に加えて規定量の試料を含む懸濁液を
作成した。該試料液を、エールリツヒ癌細胞数5
×106個を有するスイスマウス(雄)6匹の腹腔
内に0.5mlずつ9日間連続注射投与した。60日間
にわたる延命効果の結果から、平均生存日数
(MST)を求め、対照群(30匹)の平均生存日数
と比較することによりT/C%を電算機を用いて
正確に算出した。その結果を第2表に示す。[Table] Reference Example 1 Methanol (50 ml) and water (30 ml) were added to γ-(p-sulfamoylphenylureido)propyltriethoxysilane (9.07 g, 0.022 mole) obtained in Example 1, and the mixture was heated to room temperature. After stirring overnight, the mixture was heated to 60°C on a water bath for 1 hour. Low-boiling substances were distilled off from the reaction mixture under reduced pressure, and then vacuum-dried at 70°C for 5 hours to obtain γ-(p-sulfamoylphenylureido)propyl polysilsesquioxane (6.32 g) as a white solid. Obtained. Reference Example 2 A 1:1 mixture (4.00 g) of γ-[p-(bis-β-chloroethyl)aminophenylureido]propyltriethoxysilane and trimethylamine hydrochloride obtained in Example 2 was added to methanol (200 ml).
The mixture was dissolved in water, water (50 ml) was added, and the mixture was stirred at room temperature for 2 days. Methanol was removed under reduced pressure and water was decanted from the residue. Water (approximately 100 ml) was added to wash away the gum-like substance adhering to the flask. After repeating this washing operation four times, the gum state was vacuum-dried to obtain γ-[p-(bis-β-chloroethyl)aminophenylureido]propyl polycissesquioxane (2.11 g) as a pink solid. Obtained. Application example 1 Add the γ-(p-sulfamoylphenylureido)propyl polysilsesquioxane obtained in Reference Example 1 to physiological saline (0.85%) containing the surfactant Tween 80 and prepare a specified amount of sample. A suspension containing the following was prepared. The sample solution was mixed with 5 Ehrlichi cancer cells.
Six Swiss mice (male) containing ×10 6 cells were continuously injected intraperitoneally in 0.5 ml doses for 9 days. From the results of the survival effect over 60 days, the mean survival time (MST) was determined, and by comparing it with the mean survival time of the control group (30 animals), T/C% was accurately calculated using a computer. The results are shown in Table 2.
【表】
応用例 2
参考例1で得られたγ−(p−スルフアモイル
フエニルウレイド)プロピルポリシルセスキオキ
サンを界面活性剤ツイーン80を含む生理食塩水
(0.85%)溶液に懸濁させて投与量が400mg/Kgと
なるように試料溶液を調製した。この試料溶液
を、腹腔内にウオーカーカルシノサルコーマ256
癌細胞数1×105個を有するスプラグドーレイ系
ラツト(雌)6匹に対して、腹腔内注射を5日間
連続して施し、1ケ月間にわたつて延命効果を調
べた。その結果、ラツト6匹中の生存数は2であ
り、T/C%は315であつた。
応用例 3
参考例2で得られたγ−〔p−(ビス−β−クロ
ロエチル)アミノフエニルウレイド〕プロピルポ
リシスセスキオキサンを用いて実施例4で記載し
たのと同様な方法によりマウスのエールリツヒ癌
に対する制癌活性試験を行つたところ、投与量
200mg/KgにおいてT/C(%)は144であつた。
応用例 4
1.5%寒天を含む栄養培地を121℃で15分加熱滅
菌した後、50℃まで冷却し、これにあらかじめ生
育させておいた菌体または胞子を無菌水に懸濁し
たものを入れよく混ぜ、シヤーレに注入して平板
に固化させた。参考例1で得られたγ−(p−ス
ルフアモイルフエニルウレイド)プロピルポリシ
ルセスキオキサンを約3%含有しているメタノー
ル溶液に、直径8mmの円型ロ紙を浸し、ロ紙上で
余剰分を除き、固化した寒天培地上に置いた。約
30℃で24〜48時間培養後、阻止円の直径を測定し
た。その結果、稲イモチ病(Pyrichlaria
oryqae)に対し26mmφなる阻止円が観察された。
応用例 5
実施例1で合成したγ−(p−スルフアモイル
フエニルウレイド)プロピルトリエトキシシラン
を3%含有しているメタノール溶液に、直径8mm
の円型濾紙を浸し、ロ紙上で余剰分を除いた後、
該濾紙を塩酸水溶液に浸し乾燥して、有機ケイ素
化合物を濾紙上に固定した。該試料濾紙を用い
て、実施例4と同様な方法で稲イモチ病に対する
抗菌性試験を行つたところ、その阻止円は24mmφ
であつた。[Table] Application example 2 γ-(p-sulfamoylphenylureido)propyl polysilsesquioxane obtained in Reference example 1 was suspended in a saline solution (0.85%) containing the surfactant Tween 80. A sample solution was prepared so that the dose was 400 mg/Kg. Inject this sample solution into the peritoneal cavity of Walker Carcinoma Sarcoma 256.
Intraperitoneal injections were administered to 6 Sprague-Dawley rats (female) containing 1×10 5 cancer cells for 5 consecutive days, and the survival effect was investigated over a period of 1 month. As a result, the number of survivors out of 6 rats was 2, and the T/C% was 315. Application Example 3 Using γ-[p-(bis-β-chloroethyl)aminophenylureido]propylpolycissesquioxane obtained in Reference Example 2, mice were cultured in the same manner as described in Example 4. An anticancer activity test against Ehrlichi cancer revealed that the dosage
T/C (%) was 144 at 200 mg/Kg. Application example 4 A nutrient medium containing 1.5% agar is sterilized by heating at 121°C for 15 minutes, then cooled to 50°C, and pre-grown bacteria or spores suspended in sterile water are added to it. The mixture was mixed, poured into a shear plate, and solidified into a flat plate. A circular piece of paper with a diameter of 8 mm was immersed in a methanol solution containing about 3% of γ-(p-sulfamoylphenylureido)propyl polysilsesquioxane obtained in Reference Example 1. The excess was removed and placed on a solidified agar medium. about
After culturing at 30°C for 24-48 hours, the diameter of the inhibition zone was measured. As a result, rice blast disease (Pyrichlaria
oryqae), an inhibition circle of 26 mmφ was observed. Application example 5 A sample with a diameter of 8 mm was added to a methanol solution containing 3% of γ-(p-sulfamoylphenylureido)propyltriethoxysilane synthesized in Example 1.
After soaking circular filter paper and removing the excess on filter paper,
The filter paper was soaked in an aqueous hydrochloric acid solution and dried to fix the organosilicon compound on the filter paper. Using the sample filter paper, an antibacterial test against rice blast disease was conducted in the same manner as in Example 4, and the inhibition circle was 24 mmφ.
It was hot.
添付図面第1図は実施例1で得られた化合物
の、また第2図は実施例2で得られた化合物のそ
れぞれの赤外吸収スペクトルを示すチヤートであ
る。
The accompanying drawings FIG. 1 is a chart showing the infrared absorption spectra of the compound obtained in Example 1, and FIG. 2 is a chart showing the infrared absorption spectra of the compound obtained in Example 2.
Claims (1)
(β−クロロエチル)アミノ基であり、Rはアル
キル基である〕で示される置換フエニルウレイド
プロピルトリアルコキシシラン。[Claims] 1. General formula [However, X is a sulfamoyl group or a bis(β-chloroethyl)amino group, and R is an alkyl group.] A substituted phenylureidopropyltrialkoxysilane.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58176361A JPS6067485A (en) | 1983-09-26 | 1983-09-26 | Substituted phenylureidopropyltrialkoxysilane |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP58176361A JPS6067485A (en) | 1983-09-26 | 1983-09-26 | Substituted phenylureidopropyltrialkoxysilane |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6067485A JPS6067485A (en) | 1985-04-17 |
| JPS637552B2 true JPS637552B2 (en) | 1988-02-17 |
Family
ID=16012265
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP58176361A Granted JPS6067485A (en) | 1983-09-26 | 1983-09-26 | Substituted phenylureidopropyltrialkoxysilane |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JPS6067485A (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3006800A4 (en) | 2013-05-27 | 2017-03-08 | Kokusan Rasenkan Co. Ltd. | Flexible tube, flexible hose, and method for producing flexible tube |
-
1983
- 1983-09-26 JP JP58176361A patent/JPS6067485A/en active Granted
Also Published As
| Publication number | Publication date |
|---|---|
| JPS6067485A (en) | 1985-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN102863388B (en) | Tumor targeted drug Combretastatin A4 derivatives | |
| DE3767351D1 (en) | SIALOSYLCERAMIDES AND METHOD FOR THE PRODUCTION THEREOF. | |
| US4636508A (en) | 5-pyrimidinecarboxyamides and treatment of leukemia therewith | |
| JP2979469B2 (en) | New genistein derivatives | |
| SU793403A3 (en) | Method of preparing 7-/2-(2-aminothiazol-4-yl)-2-oxyiminoacetamino/-3-cephem-4-carboxylic acid derivatives | |
| JPS62174058A (en) | Drug composition for treating leukemia and tumor | |
| RU2006108577A (en) | NEW SULFENAMIDES | |
| HUT50337A (en) | Process for producing benzoxazine derivatives and pharmaceutical compositions comprising the compounds | |
| JPS637552B2 (en) | ||
| US4822817A (en) | Remedy for bone disease | |
| JPS6016924A (en) | Antineoplastic agent | |
| GB2142635A (en) | Organogermanium compound and an opioid peptide-degrading enzyme inhibitor containing the same | |
| JPH10330386A (en) | Alkoxysilane compound containing organosilyl group and carbamate bond | |
| JPS63132832A (en) | Anticonvulsivant of amino acid derivative | |
| EP4198017A1 (en) | Benzylamine derivative, preparation method therefor and use thereof | |
| JPS63264580A (en) | 3-(2-haloalkyl)-1,4-oxathiin and 2-(2- haloalkyl)-1,4-dithiin | |
| JPH0213665B2 (en) | ||
| JPH0751572B2 (en) | Heterocyclic disulfite | |
| JPS57134452A (en) | N-acyl acidic amino acid diamide, its preparation, and antiulcer agent containing the same | |
| JPS6245235B2 (en) | ||
| JPS5933292A (en) | Organogermanium compound | |
| JPS6112692A (en) | Cyclic precursor drug of antiinflammatory oxicam, manufacture and composition | |
| JPH0326698B2 (en) | ||
| JPS6023388A (en) | Organic silicon compound | |
| Danagulyan et al. | Synthesis of (2-oxo-1-pyrrolidinyl) pyrimidines |